OTHER (INCOME)/EXPENSE, NET (Tables)

12 Months Ended

Dec. 31, 2024

Other Nonoperating Income (Expense) [Abstract]

Schedule Of Other Income Expense

	Year Ended December 31,
Dollars in millions	2024		2023		2022
Interest expense	$	1,947	$	1,166	$	1,232
Royalty income - divestitures (Note 4)	(1,104)		(862)		(832)
Royalty and licensing income (Note 4)	(736)		(1,488)		(1,283)
Provision for restructuring (Note 6)	635		365		75
Investment income	(478)		(449)		(171)
Integration expenses (Note 6)	284		242		440
Litigation and other settlements (a)	84		(390)		178
Acquisition expense	50		32		—
Intangible asset impairment	47		29		—
Equity investment (gains)/losses, net (Note 9)	(16)		160		801
Loss on debt redemption (Note 10)	—		—		266
Divestiture losses/(gains) (Note 4)	15		—		(211)
Other(b)	165		37		81
Other (income)/expense, net	$	893	$	(1,158)	$	576

(a)    Includes $90 million of income related to the Eisai collaboration termination incurred in 2024.

(b)    Includes pension settlement charges of $119 million in 2024 incurred in connection with the termination of the Bristol-Myers Squibb Puerto Rico, Inc. Retirement Income pension plan.